Synergistic activation of bat SARS-like coronaviruses spike protein by elastase and TMPRSS2.

Publication date: Jul 21, 2025

Although numerous sarbecoviruses have been identified in bats, but most lack the ability to infect human cells. Some barriers limit coronavirus zoonosis, including susceptibility to host proteases. Here, we investigated whether exogenous protease treatment can circumvent host restrictions in two severe acute respiratory syndrome (SARS)-related bat coronaviruses. We found that the spike proteins of RaTG13 and Khosta-2, which are sarbecoviruses obtained from horseshoe bats in China and Russia, respectively, facilitated the ACE2-mediated entry of pseudotyped viruses into VeroE6/TMPRSS2 cells following elastase treatment. In contrast, trypsin and thermolysin exhibited no effects. Elastase-enhanced infectivity correlated with increased fusogenicity driven by the cleavage of spike proteins. This process was TMPRSS2-dependent and was inhibited by nafamostat, a TMPRSS2 inhibitor. Additionally, mutation of residue 809 within the S2 subunit of the RaTG13 spike protein (S809D) impaired elastase-induced cleavage and infectivity. Hence, proteolytic processing of the spike protein serves as a restriction to RaTG13 and Khosta-2 infections, which can be overcome by elastase. This suggests that elastase secreted in inflamed tissues during viral infection may increase the zoonotic potential of sarbecoviruses by facilitating human cell entry.

Open Access PDF

Concepts Keywords
Bat Animals
China Bat SARS-like coronavirus
Coronaviruses Benzamidines
Russia Benzamidines
Zoonosis Chiroptera
Chlorocebus aethiops
Elastase
Guanidines
Guanidines
Humans
Khosta-2
nafamostat
Pancreatic Elastase
Pancreatic Elastase
RaTG13
Serine Endopeptidases
Serine Endopeptidases
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
Spike protein
TMPRSS2 protein, human
Vero Cells
Virus Internalization

Semantics

Type Source Name
disease IDO protein
disease IDO zoonosis
disease IDO susceptibility
disease IDO host
disease MESH severe acute respiratory syndrome
drug DRUGBANK Trypsin
disease IDO infectivity
disease IDO process
drug DRUGBANK Nafamostat
disease MESH infections
disease MESH viral infection
disease IDO cell
disease MESH emerging infectious diseases
disease MESH Middle East respiratory syndrome
disease IDO infection
disease IDO replication
pathway REACTOME Budding
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
pathway KEGG Endocytosis
disease MESH inflammation

Original Article

(Visited 1 times, 1 visits today)